Quanta Fluid Solutions Ltd (Quanta), a pioneering developer of advanced haemodialysis systems, has received the CE mark for SC+, its portable, cartridge-based haemodialysis system.
SC+ is designed to bring flexibility to dialysis patients and physicians by supporting all treatment regimens, from nurse-assisted care and patient self-care in-centre to home haemodialysis. SC+ is the only portable, compact haemodialysis system with the clinical efficacy and high flow rates of traditional in-centre machines. The technology behind SC+ is based on an innovative and unique design that incorporates all fluid management activities onto a single-use disposable cartridge.
Quanta is also pleased to announce that it has raised additional funds expanding its recent investment round to a total of £29 million. The round was led by new investor ALIAD, the venture capital investment vehicle of Air Liquide SA (Paris: AI), and included participation by additional new investors Seventure Partners and Kuwait Life Sciences Company, as well as existing investors Wellington Partners, Seroba Kernel, NBGI Ventures, b-to-v Partners and IMI plc.
John E. Milad, chief executive officer of Quanta, said: "This is an exciting time for Quanta. Obtaining the CE mark for SC+ is a major milestone forus and is a testament to the ingenuity and engineering excellence of our team. SC+ is a revolutionary dialysis system based around a novel single-use disposable cartridge. Our system will provide meaningful benefits to patients and healthcare providers in terms of ease-of-use, flexibility and performance. 2014 was a transformational year for Quanta, and we are now strongly positioned to introduce SC+ for clinical use in 2015."
Professor John Agar, a practicing clinical nephrologist, Clinical Conjoint Professor of Medicine at Deakin University School of Medicine at the Geelong Hospital, Barwon Health and Member of Quanta's Medical Advisory Board, said: "Quanta's SC+ is the first real advance in dialysis system choice in a decade and a half. While small, light, and truly portable, it is still at its heart, a single pass dialysis system providing efficient and comparable dialysis to current technologies. SC+ has the benefit of transferability from centre to home, and from home to centre, which gives valuable and flexible treatment options for physicians, patients and care givers. This is a truly game-changing technology."